Greater Cannabis CO (GCAN)

Gammacan International, Inc. was incorporated under the laws of the state of Delaware on October 6, 1998 under the name of San Jose International, Inc. On August 19, 2004, the Company changed the name of its company to Gammacan International, Inc. in the State of Delaware. With the acquisition of the Intellectual Property, the Company is now focused on the commercialization of an anti-cancer immunotherapy that appears to be effective in reducing the metastatic spread of a wide range of cancers. The Company's proposed treatment will be based on intravenous immunoglobulin or IVIG, a safe, minimally-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases, and replace the antibodies in people who are unable to produce them. The Company's initial focus over the next several years is to demonstrate efficacy of IVIG cancer immunotherapy in human clinical trials. IVIG immunotherapy will require regulatory approval before being commercially marketed for human therapeutic use. Clinical trials generally include three phases that together may take several years to complete. Phase 1 clinical studies are primarily conducted to establish safety. Phase 2 studies are designed to determine preliminary efficacy. Phase 3 studies are conducted to optimize therapeutic efficacy in a statistical manner at the levels of optimal dose, method of delivery into the body or route, and schedule of administration. Once clinical trials are completed successfully, products may receive regulatory approval.